Insilico Medicine has entered a multi-year research and development collaboration with Servier worth up to $888 million to discover and develop new oncology therapies.
The partnership combines Insilico’s AI-driven drug discovery platforms with Servier’s cancer drug development expertise to target challenging oncology mechanisms and accelerate candidate identification.
Under the agreement Insilico will receive up to $32 million in upfront and near-term research payments. Servier will share R&D costs and, once promising molecules are identified, will lead clinical validation, regulatory filings and global commercialization of resulting candidates.
Insilico will lead the discovery effort using its generative AI and automation technologies to progress potential drug candidates that meet defined scientific and development criteria.
Insilico says its oncology pipeline targets several cancer indications using both novel and established mechanisms, and that its AI-enabled approach has shortened early-stage discovery timelines. From 2021 to 2024 the company nominated 20 preclinical candidates, averaging 12 to 18 months from project start to preclinical candidate while synthesising and testing 60 to 200 molecules per programme.
“I am excited to see the collaboration—it is yet another strong acknowledgement of our AI capabilities and R&D expertise,” said Insilico founder and CEO Alex Zhavoronkov. “As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development.”
Leave a Reply